Candida infections in immunocompromised hosts;Kandydiazy u chorych ze zmniejszona̧ odpornościa̧

Polski Merkuriusz Lekarski

Volumn 19, Issue 109, 2005, Pages 5-9

  Wa̧sak Szulkowska, Ewa ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Candidemia; Immunosupression; Invasive candidiasis; Mucosal candidiasis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE;

ARTICLE; CANDIDIASIS; CELL INVASION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; MICROBIOLOGICAL EXAMINATION; PROPHYLAXIS; THRUSH;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; HUMANS; IMMUNOCOMPROMISED HOST;

EID: 22244492950     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Abi-Said D., Anaissie E., Uzun O. i wsp.: The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis., 1997, 24, 1122-1128.
2. Abramowitz J., Fowler J.E., Talluri K. i wsp.: Percutaneous identification and removal of fungus ball from renal pelvis. J. Urol., 1986, 135, 1232-1233.
3. Ang B., Telenti A., King B. i wsp.: Candidemia from a urinary tract source: Microbiological aspects and clinical significance. Clin. Infect. Dis., 1993, 17, 662-666.
4. Bodey G., Luna M.: Skin lesions associated with disseminated candidiasis. JAMA, 1974, 229, 1466-1468.
5. Bougnoux M., Hill C., Moissenet D. i wsp.: Comparison of antibody, antigen, and metabolite assays for hospitalized patients with disseminated or peripheral candidiasis. J. Clin. Microbiol., 1990, 28, 905-909.
6. Bow E., Laverdiere M., Lussier N. i wsp.: Antifungal prophylaxis for severely neutropenic chemotherapy recipients - a meta-analysis of randomized-controlled clinical trials. Cancer, 2002, 94, 3230-3246.
7. Brooks R.: Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. Arch. Intern. Med.,1989, 149, 2226-2228.
8. Bross J., Talbot G.H., Meislin G. i wsp.: Risk factors for nosocomial candidemia: A case-control study in adults without leukemia. Am. J. Med., 1989, 87, 614-620.
9. Edmond M. B., Wallace S.E., McClish D.K. i wsp.: Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis., 1999, 29, 239-244.
10. Haron E., Feld R., Tuffnell P. i wsp.: Hepatic candidiasis: An increasing problem in immunocompromised patients. Am. J. Med., 1987, 83, 17-26.
11. Hughes W., Armstrong D., Bodey G.P. i wsp.: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis., 2002, 34, 730-751.
12. Krishna R., Amuh D., Lowder C.Y. i wsp.: Should all patients with Candidaemia have an ophthalmic examination to rule out ocular candidiasis? Eye, 2000, 14, 30-34.
13. Lipton S., Hickey W.F., Morris J.H. i wsp.: Candidal infection in the central nervous system. Am. J. Med., 1984, 76, 101-108.
14. Lopez-Berestein G., Bodey G.P., Frankel L.S. i wsp.: Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J. Clin. Oncol., 1987, 5, 310-317.
15. Lundstrom T., Sobel J.: Nosocomial candiduria: a review. Clin. Infect. Dis., 2001, 32, 1602-1607.
16. Maaroufi Y., Ahariz N., Husson M. i wsp.: Comparison of different methods of isolation of DNA of commonly encountered Candida species and its quantitation by using a real-time PCR-based assay. J. Clin. Microbiol., 2004, 42, 3159-3164.
17. Masur H., Rosen P., Armstrong D.: Pulmonary disease caused by Candida species. Am. J. Med., 1977, 63, 914-925.
18. Pappas P.G., Rex J.H., Sobel J.D. i wsp.: Guidelines for Treatment of Candidiasis. Clin. Infect. Dis., 2004, 38, 161-189.
19. Pastakia B., Shawker T.H., Thaler M. i wsp.: Hepatosplenic candidiasis: wheels within wheels. Radiology, 1988, 166, 417-421.
20. Pfaller M., Jones R.N., Messer S.A. i wsp.: National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. SCOPE Participant Group. Diagn. Microbiol. Infect. Dis., 1998, 30, 121-129.
21. Rello J., Esandi M.E., Diaz E. i wsp.: The role of Candida sp. isolated from bronchoscopic samples in nonneutropenic patients. Chest, 1998, 114, 146-149.
22. Revankar S., Kirkpatrick W.R., McAfee R.C. i wsp.: A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. Am. J. Med., 1998, 105, 7-11.
23. Sangeorzan J., Bradley S.F., He X. i wsp.: Epidemiology of oral candidiasis in HIV-infected patients: Colonization, infection, treatment, and emergence of fluconazole resistance. Am. J. Med., 1994, 97, 339-346.
24. Slavin M., Osbome B., Adams R. i wsp.: Efficacy and safety of fluconazole prophylaxis for fungal infections after bone marrow transplantation - a prospective, randomized, double-blind study. J. Infect. Dis., 1995, 171, 1545-1552.
25. Vartivarian S., Anaissie E., Bodey G.: Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin. Infect. Dis., 1993, 17, 487-491.
26. Walsh T., Whitcomb P.O., Ravankar S. i wsp.: Successful treatment of hepatosplenic candidiasis through repeated episodes of neutropenia. Cancer, 1995, 76, 2357-2362.
27. Walsh T., Gray W.: Candida epiglottitis in immunocompromised patients. Chest, 1987, 91, 482-485.
28. Wilcox C.: Esophageal disease in the acquired immunodeficiency syndrome: etiology, diagnosis, and management. Am. J. Med., 1992, 92, 412-421.
29. Winston D., Pakrasi A., Busuttil R.: Prophylactic fluconazole in liver transplant recipients: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med., 1999, 131, 729-737.